Get the Stockscreener App
2.10
4.55%
-0.10
Telomir Pharmaceuticals Inc stock is traded at $2.10, with a volume of 109.32K.
It is down -4.55% in the last 24 hours and down -17.32% over the past month.
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
See More
Previous Close:
$2.20
Open:
$2.14
24h Volume:
109.32K
Relative Volume:
0.69
Market Cap:
$62.50M
Revenue:
-
Net Income/Loss:
$-13.08M
P/E Ratio:
-4.7554
EPS:
-0.4416
Net Cash Flow:
-
1W Performance:
-16.00%
1M Performance:
-17.32%
6M Performance:
-50.47%
1Y Performance:
-66.67%
1-Day Range:
$2.035
$2.14
1-Week Range:
$1.98
$2.60
52-Week Range:
$1.98
$8.40
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Name
Telomir Pharmaceuticals Inc
Sector
Industry
Phone
786-396-6723
Address
100 SE 2ND ST, MIAMI
Compare TELO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
2.10 | 74.41M | 0 | -13.08M | 0 | -0.4416 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-25 | Initiated | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Stock (TELO) Latest News
Telomir Pharmaceuticals secures $3M in straight equity sale - MSN
Telomir Pharmaceuticals secures $3 million investment By Investing.com - Investing.com Canada
Telomir Pharmaceuticals appoints new CFO By Investing.com - Investing.com Nigeria
Telomir Pharmaceuticals appoints new CFO - Investing.com
Telomir Pharmaceuticals raises $3 million in equity By Investing.com - Investing.com Nigeria
Telomir Pharmaceuticals Obtains $3 Million in Straight Equity Sale - marketscreener.com
Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND - Corsicana Daily Sun
Insider Confidence: Telomir Secures $3M Premium Investment for Breakthrough Rare Disease Drug Program - Stock Titan
Telomir Pharmaceuticals raises $3 million in equity - Investing.com
EXCLUSIVE: Telomir Pharma To Raise $3 Million Via Equity Financing To Fund Its Rare Disease IND - Benzinga
TELO stock touches 52-week low at $2.26 amid market challenges - Investing.com Nigeria
Telomir Pharmaceuticals - The Pharma Letter
Telomir Pharma touts breakthrough in drug-resistant infections - The Pharma Letter
Telomir unveils new drug candidate against resistant bacteria By Investing.com - Investing.com South Africa
Telomir unveils new drug candidate against resistant bacteria - Investing.com Australia
Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity - Jonesboro Sun
First-Ever Stable Silver(II) Drug Defeats Antibiotic-Resistant Superbugs in Groundbreaking Study - Stock Titan
Barclays PLC Raises Stock Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Shares Bought by Wells Fargo & Company MN - Defense World
Telomir Pharmaceuticals (TELO) Expected to Announce Earnings on Monday - Defense World
Telomir-1 shows promise in preclinical cellular aging study By Investing.com - Investing.com South Africa
Telomir-1 shows promise in preclinical cellular aging study - Investing.com Australia
Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia - Weatherford Democrat
JPMorgan Chase & Co. Acquires 37,980 Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Geode Capital Management LLC Has $1.71 Million Stock Holdings in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
TELO stock touches 52-week low at $2.35 amid market challenges - Investing.com
TELO stock touches 52-week low at $2.46 amid market challenges By Investing.com - Investing.com South Africa
TELO stock touches 52-week low at $2.46 amid market challenges - Investing.com
Corebridge Financial Inc. Has $40,000 Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Comparing Telomir Pharmaceuticals (TELO) and The Competition - Defense World
TELO stock touches 52-week low at $2.59 amid market challenges By Investing.com - Investing.com South Africa
TELO stock touches 52-week low at $2.59 amid market challenges - Investing.com
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1 - ACCESS Newswire
Charles Schwab Investment Management Inc. Boosts Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses - ACCESS Newswire
TELO stock touches 52-week low at $3.1 amid market challenges By Investing.com - Investing.com South Africa
TELO stock touches 52-week low at $3.1 amid market challenges - Investing.com
Virtu Financial LLC Acquires Shares of 14,959 Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Bank of New York Mellon Corp Increases Stock Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Analyzing Telomir Pharmaceuticals (TELO) & The Competition - Defense World
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells - Bluefield Daily Telegraph
Telomir Pharmaceuticals Inc Stock (TELO) Financials Data
Revenue
Net Income
Cash Flow
EPS
17.27%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):